newsfilter
← Latest News
Business Wire·

Equillium Announces Feedback from the U.S. Food and Drug Administration

EQ

Equillium, Inc. (NASDAQ:EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced